Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience

Mutations in the BRAF oncogene are found in 2–4% of all non-small cell lung cancer (NSCLC) patients. The most common activating mutation present within the BRAF oncogene is associated with valine substitution for glutamate at position 600 (V600E) within the BRAF kinase. BRAF-targeted therapies are e...

Descripción completa

Detalles Bibliográficos
Autores principales: Khunger, Arjun, Khunger, Monica, Velcheti, Vamsidhar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5941661/
https://www.ncbi.nlm.nih.gov/pubmed/29595366
http://dx.doi.org/10.1177/1753466618767611

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5941661/
https://www.ncbi.nlm.nih.gov/pubmed/29595366
http://dx.doi.org/10.1177/1753466618767611

Ejemplares similares